Beactica Therapeutics

Beactica Therapeutics is a leading pharmaceutical company dedicated to pioneering innovative solutions in the fight against cancer. Specializing in the discovery and development of first-in-class therapeutics, Beactica Therapeutics leverages its cutting-edge molecular interaction-based drug discovery engine to advance a proprietary pipeline of small molecule modalities, including allosteric modulators, protein–protein interaction inhibitors, and targeted protein degraders (PROTACs).

Located at Virdings allé 2, Uppsala, SE-754 50, SE, and with an additional site at Uppsala Business Park, Rapsgatan 7, Uppsala, SE-754 50, SE, Beactica Therapeutics is committed to targeting genetically defined cancers with precision and efficacy. Through a synergistic approach, Beactica Therapeutics aims to transform the landscape of cancer treatment, offering new hope and improved outcomes for patients worldwide.

Beactica Therapeutics continues to drive advancements in therapeutics and drug discovery, solidifying its position as a key player in the pharmaceutical industry. We invite the management team at Beactica Therapeutics to enhance your company's visibility by creating a customized and exclusive company showcase and product listing on our platform.